Enhancing glucose sensor models: modeling the drop-outs.

abstract：:Subcutaneous (s.c.) injections of identical insulin doses may lead to considerable intra- and inter-individual differences in the current metabolic control of patients with diabetes mellitus. This well-known variability of the metabolic effect of insulin hampers practical insulin therapy considerably. The aim of this ...

journal_title：Diabetes technology & therapeutics

authors： Heinemann L

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:The OpT2mise randomized trial was designed to compare the effects of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) on glucose profiles in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS:Patients with glycated hemoglobin (HbA1c) levels of ≥8% (64 mmol/mol) and...

journal_title：Diabetes technology & therapeutics

authors： Conget I,Castaneda J,Petrovski G,Guerci B,Racault AS,Reznik Y,Cohen O,Runzis S,de Portu S,Aronson R,OpT2mise Study Group.

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:Adherence to established standards (e.g., International Organization for Standardization [ISO] 15197) is important to ensure comparable and sufficient accuracy of systems for self-monitoring of blood glucose (SMBG). Accuracy evaluation was performed for different SMBG systems available in Europe with three r...

journal_title：Diabetes technology & therapeutics

authors： Freckmann G,Link M,Schmid C,Pleus S,Baumstark A,Haug C

更新日期：2015-09-01 00:00:00

abstract：BACKGROUND:Currently, two systems for continuous tissue glucose monitoring (CGM) (Dexcom® G5 [DG5] and FreeStyle Libre [FL]) are intended to replace blood glucose monitoring (BGM) and, according to manufacturer labeling, are distributed as such in some jurisdictions, including the United States and the European Union. ...

journal_title：Diabetes technology & therapeutics

authors： Freckmann G,Link M,Pleus S,Westhoff A,Kamecke U,Haug C

更新日期：2018-08-01 00:00:00

abstract：: Background: International consensus on the use of continuous glucose monitoring (CGM) recommends coefficient of variation (CV) as the metric of choice to express glycemic variability (GV) with a cutoff of 36% to define unstable diabetes. Even though, CV is associated with ...

journal_title：Diabetes technology & therapeutics

authors： Gómez AM,Henao DC,Imitola Madero A,Taboada LB,Cruz V,Robledo Gómez MA,Rondón M,Muñoz-Velandia O,García-Jaramillo M,León Vargas FM

更新日期：2019-08-01 00:00:00

abstract：BACKGROUND:The purpose of this study is to test the agreement between energy expenditure estimate of the SenseWear(®) Armband Pro3 (SWA) (BodyMedia, Pittsburgh, PA) and the Omron HJ-720 (Omron Healthcare, Kyoto, Japan) step counter with indirect calorimetry (IC) as a gold standard in older individuals with type 1 and t...

journal_title：Diabetes technology & therapeutics

authors： Machač S,Procházka M,Radvanský J,Slabý K

更新日期：2013-05-01 00:00:00

abstract：BACKGROUND:Continuous glucose monitoring (CGM) technologies report measurements of interstitial glucose concentration every 5 min. CGM technologies have the potential to be utilized for prediction of prospective glucose concentrations with subsequent optimization of glycemic control. This article outlines a feed-forwar...

journal_title：Diabetes technology & therapeutics

authors： Pappada SM,Cameron BD,Rosman PM,Bourey RE,Papadimos TJ,Olorunto W,Borst MJ

更新日期：2011-02-01 00:00:00

abstract：:Laser retinal photocoagulation represents the primary therapy for the potentially blinding manifestations of diabetic retinopathy. Advances in laser therapy for diabetic eye disease have arisen from the convergence of laser technology and clinical ophthalmology. In this review, the basis of laser therapy in diabetic r...

journal_title：Diabetes technology & therapeutics

authors： Petrovic V,Bhisitkul RB

更新日期：1999-07-01 00:00:00

abstract：: Background: This observational study investigated whether the connected NovoPen® 6 could influence insulin regimen management and glycemic control in people with type 1 diabetes (T1D) using a basal-bolus insulin regimen and continuous glucose monitoring in a real-world set...

journal_title：Diabetes technology & therapeutics

authors： Adolfsson P,Hartvig NV,Kaas A,Møller JB,Hellman J

更新日期：2020-10-01 00:00:00

abstract：:Self-monitoring of blood glucose was described as one of the most important advancements in diabetes management since the invention of insulin in 1920. Recent advances in glucose sensor technology for measuring interstitial glucose concentrations have challenged the dominance of glucose meters in diabetes management, ...

journal_title：Diabetes technology & therapeutics

authors： Cengiz E,Tamborlane WV

更新日期：2009-06-01 00:00:00

abstract：:There is a clear role for inflammation in the development of type 2 diabetes and its associated co-morbidities. Circulating inflammatory markers such as C-reactive protein, sialic acid, and interleukin- 6 are all significant independent predictors of disease. A number of nutritional components are hypothesized to modu...

journal_title：Diabetes technology & therapeutics

authors： Browning LM,Jebb SA

更新日期：2006-02-01 00:00:00

abstract：:Current clinical guidelines for diabetes care encourage self-monitoring of blood glucose (SMBG) to improve glycemic control. Specific protocols remain variable, however, particularly among non-insulin-using patients. This is due in part to efficacy studies that neglect to consider (1) the performance of monitoring equ...

journal_title：Diabetes technology & therapeutics

authors： Hirsch IB,Bode BW,Childs BP,Close KL,Fisher WA,Gavin JR,Ginsberg BH,Raine CH,Verderese CA

更新日期：2008-12-01 00:00:00

abstract：BACKGROUND:Insulin initiation and optimization is a challenge for patients with type 2 diabetes. Our objective was to determine whether safety and efficacy of AIR inhaled insulin (Eli Lilly and Co., Indianapolis, IN) (AIR is a registered trademark of Alkermes, Inc., Cambridge, MA) using a simplified regimen was noninfe...

journal_title：Diabetes technology & therapeutics

authors： Mathieu C,Cuddihy R,Arakaki RF,Belin RM,Planquois JM,Lyons JN,Heilmann CR

更新日期：2009-09-01 00:00:00

abstract：OBJECTIVE:This study was designed to measure pressure and shear reduction of a novel insole design. METHODS:We compared three multilayer viscoelastic insoles to a novel insole design (Glide-Soft, Xilas Medical, Inc., San Antonio, TX). The bottom pad of each insole was fabricated from firm-density Plastazote [Apex Foot...

journal_title：Diabetes technology & therapeutics

authors： Lavery LA,Lanctot DR,Constantinides G,Zamorano RG,Athanasiou KA,Agrawal CM

更新日期：2005-08-01 00:00:00

abstract：BACKGROUND:The junction of telemedicine home monitoring with multifaceted disease management programs seems nowadays a promising direction to combine the need for an intensive approach to deal with diabetes and the pressure to contain the costs of the interventions. Several projects in the European Union and the United...

journal_title：Diabetes technology & therapeutics

authors： Bellazzi R,Arcelloni M,Ferrari P,Decata P,Hernando ME,García A,Gazzaruso C,Gómez EJ,Larizza C,Fratino P,Stefanelli M

更新日期：2004-10-01 00:00:00

abstract：BACKGROUND:Applying real-time learning into an artificial pancreas system could effectively track the unpredictable behavior of glucose-insulin dynamics and adjust insulin treatment accordingly. We describe a novel learning algorithm and its performance when integrated into the MD-Logic Artificial Pancreas (MDLAP) syst...

journal_title：Diabetes technology & therapeutics

authors： Miller S,Nimri R,Atlas E,Grunberg EA,Phillip M

更新日期：2011-10-01 00:00:00

abstract：:Most previous attempts at the development of a "smart tattoo" for glucose monitoring in diabetes--implantable fluorescent microspheres that can be implanted intradermally and interrogated transdermally using light--have focused on the encapsulation of a competitive binding assay for glucose within hydrogel microsphere...

journal_title：Diabetes technology & therapeutics

authors： Brown JQ,Srivastava R,Zhu H,McShane MJ

更新日期：2006-06-01 00:00:00

abstract：BACKGROUND:Patients undergoing intensive insulin therapy may have blood glucose (BG) samples drawn from arterial, capillary, or venous sources. This study compared capillary and venous BG across a range of glucose concentrations and under conditions of rapid change in BG. METHODS:Following a 10-h fast, 40 adult patien...

journal_title：Diabetes technology & therapeutics

authors： Kempe K,Price D,Ellison J,Marhoul J,Morrow L,Win K,Kuschma K,Hompesch M

更新日期：2009-10-01 00:00:00

abstract：BACKGROUND:The purpose of this study was to evaluate the performance of an insulin infusion protocol targeting a blood glucose (BG) level of 140-180 mg/dL and to characterize protocol adherence. MATERIALS AND METHODS:This was a retrospective observational cohort study including patients for whom the protocol was order...

journal_title：Diabetes technology & therapeutics

authors： Passarelli AJ,Gibbs H,Rowden AM,Efird L,Zink E,Mathioudakis N

更新日期：2016-02-01 00:00:00

abstract：:It is becoming increasingly acknowledged that people with Type 2 Diabetes represent what can be termed "an enriched population": a group that has the greatest risk of morbidity and mortality from cardiovascular diseases such as myocardial infarcts and strokes. Due to the tremendous toll, both human and financial, that...

journal_title：Diabetes technology & therapeutics

authors： Marcus AO

更新日期：2000-07-01 00:00:00

abstract：BACKGROUND:The Optimizing Control in Diabetes (OPTIMIZE) survey was conducted to understand the patients' perspective to achieving good glycemic control and to determine how patients' perceptions of insulin may affect their decisions to initiate or intensify their insulin therapy. METHODS:A total of 1,444 subjects wit...

journal_title：Diabetes technology & therapeutics

authors： Cefalu WT,Mathieu C,Davidson J,Freemantle N,Gough S,Canovatchel W,OPTIMIZE Coalition.

更新日期：2008-02-01 00:00:00

abstract：:AIDA is a diabetes-computing program freely available from www.2aida.org on the Web. The software is intended to serve as an educational support tool, and can be used by anyone who has an interest in diabetes, whether they be patients, relatives, health-care professionals, or students. In previous "Diabetes Informatio...

journal_title：Diabetes technology & therapeutics

authors： Lehmann ED

更新日期：2003-01-01 00:00:00

abstract：:Recent years have brought about an explosion in the number of companies offering connected diabetes care products, defined as digital diabetes management systems based around (1) smartphone apps, (2) devices with built-in connectivity, and (3) remote human and automated coaching and support. These nascent models aim t...

journal_title：Diabetes technology & therapeutics

authors： Levine BJ,Close KL,Gabbay RA

更新日期：2020-01-01 00:00:00

abstract：: Background: We aimed to explore insulin pump settings in breastfeeding women with type 1 diabetes. Methods: Thirteen unselected breastfeeding women with type 1 diabetes on insulin pump therapy were included consecutively from A...

journal_title：Diabetes technology & therapeutics

authors： Nørgaard SK,Nørgaard K,Roskjær AB,Mathiesen ER,Ringholm L

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:Diabetic foot ulcer area is a basic parameter used for monitoring the wound healing and effectiveness of the treatment applied. TeleDiaFoS (developed earlier in collaboration with the Department and Clinic of Gastroenterology and Metabolic Diseases, Medical University of Warsaw, Warsaw, Poland) is one of jus...

journal_title：Diabetes technology & therapeutics

authors： Ladyzynski P,Foltynski P,Molik M,Tarwacka J,Migalska-Musial K,Mlynarczuk M,Wojcicki JM,Krzymien J,Karnafel W

更新日期：2011-11-01 00:00:00

abstract：: Background: Continuous subcutaneous insulin infusion (CSII) is associated with improved glycemic control, a reduced incidence of hypoglycemia, and improved quality of life (QOL). To date, however, there has been no QOL scale specific to CSII. The objective of this study wa...

journal_title：Diabetes technology & therapeutics

authors： Sakane N,Murata T,Tone A,Kato K,Kimura M,Kawashima S,Sawaki H,Hirota Y,Okada A,Kuroda A,Matsuhisa M,Watanabe T,Suganuma A,Nirengi S,Toyoda M

更新日期：2020-03-01 00:00:00

abstract：AIMS:This study assessed patient-reported outcomes in a multicenter study of adults with type 2 diabetes taking mealtime Technosphere(®) inhaled insulin (MannKind Corp., Valencia, CA) and basal insulin (insulin glargine) or premixed aspart insulin 70/30. METHODS:Subjects were 618 non-smoking adults with starting hemog...

journal_title：Diabetes technology & therapeutics

authors： Peyrot M,Rubin RR

更新日期：2011-12-01 00:00:00

abstract：OBJECTIVE:The purpose of the present study was to determine the effectiveness of a fluorescent contact lens glucose sensor in monitoring glucose in patients with diabetes. METHODS:Under an institutional review board-approved protocol, five fasting patients with type II diabetes were given a challenge consisting of 75 ...

journal_title：Diabetes technology & therapeutics

authors： March WF,Mueller A,Herbrechtsmeier P

更新日期：2004-12-01 00:00:00

abstract：BACKGROUND:This study was designed to assess the accuracy, reliability, and contribution to clinical decision-making of two commercially available continuous glucose monitoring (CGM) devices using a novel analytical approach. STUDY DESIGN:Eleven individuals with type 1 diabetes and five with type 2 diabetes wore a Gua...

journal_title：Diabetes technology & therapeutics

authors： Mazze RS,Strock E,Borgman S,Wesley D,Stout P,Racchini J

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:The masked continuous glucose monitoring system (Masked-CGMS) differs from standard CGMSs in three ways: (1) there is no feedback to the user so that no immediate regimen changes can be made; (2) it can only be worn for up to 5 days; and (3) there are no alarms to warn of hyperglycemia or hypoglycemia. Since...

journal_title：Diabetes technology & therapeutics

authors： Duran-Valdez E,Burge MR,Broderick P,Shey L,Valentine V,Schrader R,Schade DS

更新日期：2014-05-01 00:00:00